COMMUNIQUÉS West-GlobeNewswire

CrazyBulk: SARM Alternatives for Bulking, Strength and Performance or Just Hype?
30/01/2026
New York City, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Visit Official CrazyBulk Website Here TL;DR Summary: A lot of athletes, whether they are professionals or just training for personal goals, eventually hit a point [...]
Dr. Linette Williamson Expands Integrative Medicine Services in Encinitas With Physician-Supervised Ozone Sauna Therapy
30/01/2026
Encinitas, CA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Dr. Linette Williamson, MD, a physician with extensive experience in emergency medicine and integrative functional care, is expanding the therapeutic services offered at [...]
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
30/01/2026
LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
30/01/2026
FDA sets PDUFA target action date of July 23, 2026 FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical [...]
IO Biotech Provides Corporate Update
30/01/2026
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune- [...]
ALX Oncology Announces Pricing of Underwritten Offering
30/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
30/01/2026
PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
30/01/2026
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by [...]
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
30/01/2026
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be presented at [...]
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
30/01/2026
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, [...]
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
30/01/2026
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate that [...]
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
30/01/2026
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted [...]
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
30/01/2026
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy [...]
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
30/01/2026
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
30/01/2026
Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of Pain [...]
Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy
30/01/2026
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the parent company of Alps Life Sciences Inc. (“ Alps Holdco ”), a fully integrated biotechnology research [...]
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
30/01/2026
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and [...]
Standard BioTools Completes Sale of SomaLogic to Illumina
30/01/2026
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, [...]

Pages